+1 (505) 492-0979
sales: info@indicalab.com
support: support@indicalab.com
mobile logo

Immuno-oncology

Indica Labs / Immuno-oncology

Multiomic analysis and immunoprofiling reveal distinct subtypes of human angiosarcoma

by admin
HALO Publications, Immuno-oncology
March 16, 2021

Jason Yongsheng Chan,et al, The Journal of Clinical Investigation, 2020
To molecularly characterize the rare and aggressive tumors known as angiosarcomas, Chan et al utilized a combination of transcriptomic immuno-oncology profiling with multiplex immunohistochemistry and immunofluorescence. HALO image analysis software was used for the quantification of PD-L1, CD68, CD8, FOXP3, CD15, and ERG. From these studies, three phenotypes of patients were identified according to etiology, anatomical origin, signaling pathways, and the tumor inflammation signature. These distinct biological phenotypes...

,

An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer

by admin
HALO Publications, Immuno-oncology
March 16, 2021

Dr. Paula Voabil and colleagues used a patient derived tumor fragment platform to investigate immune responses immediately following PD-1 blockade. The Tissue Classifier Add-on and the Multiplex IHC module of HALO® were used in this publication to quantify immune biomarkers in the tumor and stroma, contributing to their conclusion that the ability of tumors to respond to PD-1 blockage correlates with the ability of intratumoral immune cells to be reactivated by the blockade....

Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers

by admin
Immuno-oncology, Publications
March 16, 2021

Myriam Chalabi, et al, Nature Medicine, 2020
Immunotherapy is known to be effective in late-stage, mismatch repair (MMR) deficient colorectal cancers but not in MMR proficient cancer. This study reports the early results from the NICHE clinical trial that is evaluating treatment of early stage, nonmetastatic preoperative colon cancer with a CTLA-4 inhibitor and a PD-1 inhibitor. Chalabi and colleagues report that the treatment was well tolerated and that a major pathological response was seen in 19/20 patients with...

,

Natural killer cells in the human lung tumor microenvironment display immune inhibitory functions

by admin
HALO Publications, Immuno-oncology
March 16, 2021

Jules Russick, et al, Journal for ImmunoTherapy of Cancer, 2020
Natural killer (NK) cells are known to have cytotoxic effector functions in tumor immunosurveillance. More recently, evidence of a second potentially inhibitory or regulatory role have emerged. Here, Russick et al compared expression patterns of NK cells inside tumors to nontumoral NK cells to understand their inhibitory functions in the context of the non-small cell lung carcinoma (NSCLC) tumor microenvironment (TME). These studies identified a novel and specific...

Intratumoral interleukin-12 mRNA therapy promotes TH1 transformation of the tumor microenvironment

by admin
Immuno-oncology, Publications
March 16, 2021

Susannah L Hewitt, et al, Clinical Cancer Research, 2020
In patients with advanced stage lung disease, it is beneficial to evaluate candidacy for immunotherapy without invasive biopsy testing. Lou et al performed a concordance study to evaluate formalin fixed cell blocks compared to lung tumor resections using a PD-L1 22C3 IHC pharmDx™ assay and found strong concordance between pathologists and HALO image analysis software. Future research will focus on clinical validation by assessing the clinical benefit from immunotherapy following PD-L1 immunohistochemistry...

, ,
ABOUT INDICA LABS
Indica Labs is the world’s leading provider of computational pathology software and services. Our flagship HALO® image analysis platform enables fast, quantitative evaluation of tissues using a broad range of artificial intelligence (AI) and computer vision algorithms. HALO Link™ and HALO AP® facilitate remote image analysis, collaboration and management. Through a combination of precision, performance, scalability, and usability our software solutions enable pharmaceutical companies, diagnostic labs, research organizations, and Indica’s own contract pharma services team to advance tissue-based research, clinical trials, and diagnostics.

© 2011-2022 Indica Labs Inc. All rights reserved.

CAREERS
Interested in working for Indica Labs?  Check out our CAREERS page. 
CONTACT US
EMAIL

Tech Support        support@indicalab.com
HR Inquires                   hr@indicalab.com
All other Inquires        info@indicalab.com

PHONE
US Headquarters +1 (505) 492-0979
United Kingdom  +44 (0) 333 090 1113 
 Japan | 日本事務所  +81 (0)3 3525 4158
China +86 13761896143
COVID-19 Notice:

All departments remain fully functional and we are committed to supporting customers during this time. For more information please read COVID-19 Technical Guidance.
Contact support@indicalab.com for any questions or concerns.